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Although cardioplegia reduces myocardial metabo- 
lism during ischemia, adenosine triphosphate (ATP) 
depletion occurs, which may contribute to poor func- 
tional recovery after reperfusion. Augmenting myo- 
cardial adenosine during ischemia is successful in im- 
proving ATP repletion and myocardial recovery follow- 
ing ischemia. If adenosine is an important determinant 
of ischemic tolerance, then depletion or elimination of 
myocardial adenosine should lead to poor functional 
and metabolic recovery after ischemia. To test this hy- 
pothesis, isolated, perfused rabbit hearts were sub- 
jected to 120 min of 34°C ischemia. Hearts received St. 
Thomas cardioplegia alone or cardioplegia containing 
200 FM adenosine, or cardioplegia containing 15, 5, 
2.5, or 0.025 pg/ml adenosine deaminase (ADA), which 
catalyzes the breakdown of adenosine to inosine, mak- 
ing adenosine unavailable as an ATP precursor. Func- 
tional recovery was determined and myocardial nu- 
cleotide levels were measured before, during, and after 
ischemia. Following ischemia and reperfusion, control 
hearts recovered to 51 * 3% of preischemic developed 
pressure (DP). There was significantly better recovery 
in adenosine-augmented hearts (68 * 7%), while ADA 
hearts had significantly worse recovery. Hearts 
treated with 0.025 pg/ml ADA recovered to only 29 
-+ 5% of DP and higher dose ADA hearts failed to dem- 
onstrate any recovery of systolic function. Further- 
more, adenosine enhanced metabolic recovery, 
whereas ADA resulted in greatly depleted ATP and 
precursor reserves. Postischemic developed pressure 
closely paralleled the availability of myocardial adeno- 
sine, consistent with the hypothesis that myocardial 
adenosine levels at end ischemia and early reperfusion 
are important determinants of functional recovery 
after global ischemia. 0 1991 Academic Press, Inc. 
INTRODUCTION 
To provide myocardial protection during cardiac sur- 
gery, cardioplegia and myocardial hypothermia are uti- 
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lized routinely. Despite these protective techniques, how- 
ever, adenosine triphosphate (ATP) depletion may oc- 
cur during ischemia. The slow recovery of the depleted 
nucleotides, especially ATP, following ischemia is well 
recognized. Since intracellular ATP is essential for myo- 
cardial contraction and relaxation, ATP depletion may 
be an important factor contributing to the incomplete 
recovery of ventricular function following ischemia and 
reperfusion. The decrease in ATP during ischemia is not 
accompanied by a rise in ADP, as ADP is quickly trans- 
formed to AMP. The dephosphorylation of AMP by 
5’-nucleotidase results in formulation of adenosine 
which is deaminated to inosine by adenosine deaminase. 
Since the nucleosides can exit the myocyte, they are 
washed out of the interstitial space during reflow and are 
unavailable for the nucleotide salvage pathway. 
Previous studies [l-5] have demonstrated that adeno- 
sine-supplemented cardioplegia was associated with ac- 
celerated repletion of ATP and improved functional re- 
covery after reperfusion. Two-deoxycoformycin, an 
agent that inhibits adenosine deaminase, was also 
shown to be beneficial [3], supporting the view that 
adenosine availability during and after global ischemia 
may be an important determinant of postischemic meta- 
bolic and functional recovery. If this hypothesis is 
correct, then depletion or elimination of myocardial 
adenosine should lead to poor functional and metabolic 
recovery after ischemia. 
Cardioplegia containing adenosine deaminase was ad- 
ministered to isolated, perfused rabbit hearts subjected 
to global ischemia. Adenosine deaminase was used to 
accelerate the breakdown of adenosine, limiting its avail- 
ability as an ATP precursor. The effects of adenosine 
depletion on functional and metabolic recovery were 
compared with the results obtained when adenosine lev- 
els were augmented and with a control group of isolated 
hearts treated with cardioplegia alone. 
MATERIAL AND METHODS 
Studies were performed in isolated, perfused rabbit 
hearts. Male New Zealand White rabbits (3 to 4 kg) were 
anesthetized and cardiectomy was performed. The beat- 
ing heart was suspended from a perfusion column by 
aortic cannulation and coronary perfusion was estab- 
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lished at 80 mm Hg. The perfusate used was a modified, 
oxygenated Krebs-Ringer bicarbonate solution (pH 7.44 
to 7.48, 37”C, 300 to 310 mOsm/liter), with an oxygen 
tension of 550 and 650 torr. The perfusion solution was 
filtered and was not recirculated. 
While the heart was perfused on the column, a portion 
of the mitral valve with its chordae was excised and a 
latex balloon, connected to saline-filled tubing, was in- 
troduced into the left ventricle (LV) through the mitral 
orifice. The balloon was sewn in place in such a way to 
allow for passive venting of the LV cavity. The balloon 
was connected through a catheter to a pressure trans- 
ducer, and LV pressure was recorded continuously. Out- 
put from the pressure transducer was electronically dif- 
ferentiated to enable continuous recording of dP/dt. 
During the preischemic control period, a volume of 
saline was introduced into the LV balloon to produce an 
end-diastolic pressure (EDP) of 10 mm Hg. The same 
volume was used to evaluate ventricular systolic perfor- 
mance during reperfusion. Coronary flow was measured 
volumetrically. A thermistor needle was inserted into 
the midmyocardium to record myocardial temperature. 
After a 30-min stabilization period, control measure- 
ments of end-diastolic pressure (EDP), developed pres- 
sure (DP, peak systolic pressure minus end-diastolic 
pressure), peak positive dP/dt, and coronary flow were 
made in each heart. Hearts were then rendered globally 
ischemic. The intraventricular balloon was deflated and 
60 ml of cardioplegia was administered. All hearts were 
maintained at 34°C by means of a circulating water 
jacket during 120 min of total ischemia. All hearts re- 
ceived 15 ml of cardioplegia every 30 min during isch- 
emia. Control hearts (n = 9) received modified St. 
Thomas cardioplegia alone, while experimental hearts 
received modified St. Thomas cardioplegia plus 200 PM 
adenosine (n = 9) or adenosine deaminase 15,5,2.5, or 
0.025 pg/ml of cardioplegia (n = 5, 5, 5, and 4, respec- 
tively) . 
Reperfusion was performed with perfusate tempera- 
ture at 37°C and delivered with pressure at 80 mm Hg. 
Defibrillation was performed as needed. During the ini- 
tial 15 min of reperfusion, the intraventricular balloon 
was kept deflated to simulate the beating, nonworking 
condition. After the initial 15 min of reperfusion, the LV 
balloon was refilled to the preischemic control volume 
and measurements of EDP, DP, dP/dt, and coronary 
flow were made. The balloon remained inflated for the 
remainder of reperfusion. LV functional measurements 
were obtained after 15, 30, and 45 min of reperfusion. 
After 45 min of reperfusion, all hearts were removed 
from the perfusion apparatus. This experimental design 
for this model is well established and has been published 
previously [3, 41. 
A parallel series of experiments were done concur- 
rently in an identical fashion to determine myocardial 
nucleotide levels. Control hearts (n = 4) received modi- 
fied St. Thomas cardioplegia, while experimental hearts 
received modified St. Thomas cardioplegia with the ad- 
dition of 200 PM adenosine (n = 4) or adenosine deami- 
nase 15, 5, 2.5, or 0.025 /*g/ml of cardioplegia (n = 4 
each). Specimens were taken from the left ventricle with 
a biopsy gun during the control period, prior to reflow (at 
end ischemia), and 1 and 15 min during reperfusion. The 
biopsy specimens were frozen in liquid nitrogen immedi- 
ately after they were obtained. 
The specimens were assayed by the high performance 
liquid chromatography (HPLC) method for myocardial 
cellular ATP, ADP, AMP, adenosine, and phosphocre- 
atine levels and values are expressed as micromoles of 
nucleotide per milligram of protein. Statistical analysis 
was performed with analysis of variance and Student’s 
two-tailed t test, where appropriate. A P value of less 
than 0.05 was considered significant. All results are ex- 
pressed as means f SEM. All animals received humane 
care in compliance with the Principles of Laboratory An- 
imal Care formulated by the National Society for Medi- 
cal Research. 
RESULTS 
Left Ventricular Function 
There were no significant differences in the prearrest 
DP, dP/dt, or heart rates between control hearts and 
those receiving adenosine or adenosine deaminase for 
any group. Left ventricular systolic functional measure- 
ments of DP and + dP/dt were made after 15,30, and 45 
min of reperfusion. Left ventricular EDP was also mea- 
sured in 15-min intervals following reperfusion and was 
expressed as an increase in EDP over the preischemic 
control EDP value of 10 mm Hg. 
After 120 min of hypothermic ischemia and 45 min of 
reperfusion control hearts recovered to 51 f 3% of the 
preischemic DP. There was significantly better recovery 
of LV function in the adenosine-augmented hearts with 
68 + 7% recovery of DP in the hearts treated with 200 
PM exogenous adenosine (P < 0.05 vs control hearts). 
However, the adenosine deaminase (ADA)-treated 
hearts had significantly worse recovery of function than 
those of the control hearts. Hearts treated with 0.025 
pg/ml ADA recovered to only 29 f 5% of preischemic DP 
and higher dose ADA hearts failed to demonstrate any 
recovery of systolic function (Table 1). 
Left ventricular EDP, an estimate of diastolic func- 
tion in this model, was significantly lower at all times 
during reperfusion in the adenosine-treated (ADO)-aug- 
mented hearts compared with control. After 45 min of 
reperfusion, control hearts demonstrated elevated left 
ventricular end-diastolic pressures with a 24 -I- 4 mm Hg 
rise in LVEDP, whereas the 200 PM adenosine hearts 
had only a 16 f 4 mm Hg elevation in LVEDP. The ADA 
hearts displayed a 40 + 8 mm Hg, 39 & 7 mm Hg, 52 * 6 
mm Hg, and 59 +- 2 mm Hg rise in LVEDP, with ADA 
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TABLE 1 
Functional Recovery 45 Min following Reperfusion 
N %DP dEDP CF 
ADO 9 68 + 7* 16 f 4* 38 f 7 
CTL 9 51+ 3 24 -r- 4 36 + 4 
ADA-O.025 &ml 4 29 -t 5* 40 f &3* 35 * 7 
ADA-Z.5 pg/ml 5 Of 39 f 7* 31 k 6 
ADA-5 pg/ml 5 0* 52 f 6* 40 k 6 
ADA-15 pg/ml 5 0* 59 + 2* 31 * 5 
Note. ADO, adenosine treated hearts; CTL, control hearts; ADA, 
hearts treated with adenosine deaminase; %DP, recovery of developed 
pressure presented as a percentage return of preischemic developed 
pressure; dEDP, change in end diastolic pressure following reperfu- 
sion as compared to preischemic baseline isovolumic end diastolic 
pressure; CF, coronary flow. 
* P < 0.05 vs controls. 
doses of 0.025 pg/ml, 2.5 pg/ml, 5 pg/ml, and 15 hg/ml, 
respectively, in the cardioplegia (Table 1). 
Coronary flow during reperfusion demonstrated no 
differences among any of the groups. Preischemic coro- 
nary flow values were also similar in all of the groups. 
Finally, heart rates demonstrated no significant differ- 
ences among any of the groups following reperfusion. 
Nucleotide Levels 
Adenosine, AMP, ADP, and ATP were measured in 
the control, adenosine, and adenosine deaminase groups 
(n = 4 each) before, during, and following ischemia. Re- 
sults are expressed as PM of nucleotide per milligram of 
protein (measured by Lowry assay) and are summarized 
in Table 2. Baseline readings of adenosine (2.4 & 0.3 
pM/mg protein) and ATP (2.6 I~I 0.8 pM/mg protein) 
were equivalent in all groups. 
During ischemia, ATP levels decreased in all groups. 
The end-ischemic ATP level was reduced to approxi- 
mately 0.8 pM/mg protein in the control, adenosine- 
augmented, and low dose ADA groups, while ATP was 
essentially eliminated in the high dose ADA groups. Also 
during ischemia, myocardial adenosine was depressed in 
the control and low dose ADA groups, increased in the 
ADO-treated group, and reduced to zero in the high dose 
ADA groups during ischemia. Control hearts were char- 
acterized by adenosine levels of 2.0 + 0.12 pM/mg at end 
ischemia; the values were 5.6 f 0.17 in the adenosine- 
treated group (P < 0.05 vs control). Hearts treated with 
ADA had no measurable adenosine except in the 0.025 
pg/ml ADA group, which had adenosine levels of 1.6 
f 0.03 pM/mg at end ischemia. 
During reperfusion, both at 1 and 15 min following 
reflow, control hearts remained characterized by de- 
pressed adenosine levels (1.9 -+ 0.5 and 1.5 + 0.07 pM/mg 
protein). ATP levels also remained low in the control 
group with values of only 1.8 k 0.05 and 1.3 + 0.19 pM/ 
mg at 1 and 15 min following reperfusion, respectively. 
In comparison, adenosine-treated hearts had high 
postischemic adenosine levels (5.9 + 0.09 and 4.0 + 0.11 
pM/mg, 1 and 15 min following reflow). The adenosine- 
treated hearts also had substantially higher levels of 
ATP at 1 and 15 min following reflow with levels of 5.9 
f 0.05 and 6.0 -t 0.07 pM/mg, respectively (P < 0.05 vs 
control). 
Low dose ADA (0.025 pg/ml)-treated hearts had 
adenosine levels of 1.8 f 0.02 and 0 FM/mg at 1 and 15 
min following reperfusion. Furthermore, this lowest 
dose ADA-treated group (0.025 fig/ml) was character- 
ized by depressed levels of ATP immediately after reper- 
fusion and elimination of ATP 15 min postreperfusion. 
Consistent with the experimental hypothesis, higher 
dose ADA-treated (2.5,5, and 15 pg/ml adenosine deami- 
nase) hearts displayed complete depletion of adenosine 
and also ATP during and after ischemia. 
DISCUSSION 
In the present study, postischemic developed pressure 
closely paralleled the availability of myocardial adeno- 
sine (Fig. l), consistent with the hypothesis that myo- 
TABLE 2 
Metabolic Recovery 45 Min following Reperfusion 
AD 
Ischemia 1 Min reflow 15 Min reflow 
ATP AD ATP AD ATP 
ADO 5.6 k 17* 0.8 + 0.04 5.9 + 0.09* 5.9 i 0.05* 4.0 f 0.11* 6.0 f 0.07* 
CTL 2.0 * 0.12 0.8 I 0.01 1.9 -c 0.05 1.8 +- 0.05 1.5 + 0.07 1.3 * 0.19 
ADA-O.025 fig/ml 1.6 k 0.03 1.1 f 0.01 1.8 f 0.02 1.3 f 0.02 0* 0* 
ADA-Z.5 pg/ml 0* 0* 0* 0* 0* 0* 
ADA-5 gg/ml 0* 0* 0* 0* 0* 0’ 
ADA-15 rg/ml 0* 0* 0* 0* 0* 0* 
Note. ADO, adenosine-treated hearts; CTL, control hearts; ADA, adenosine deaminase-treated hearts; nucleotide levels are presented as pM 
of nucleotide/mg of protein; AD, nucleotide levels of adenosine; ATP, nucleotide levels of adenosine triphosphate. 
* P < 0.05 vs controls. 
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FIG. 1. Correlation of end-ischemic adenosine vs eventual return 
of LV function and postischemic end diastolic pressure (45 min post- 
reperfusion). 
cardial adenosine levels at end ischemia and early reper- 
fusion are important determinants of functional recov- 
ery. ATP depletion occurred during ischemia; however, 
ATP content did not predict myocardial recovery follow- 
ing ischemia. Additionally, postischemic end-diastolic 
pressure was inversely correlated to myocardial adeno- 
sine levels, not ATP at end ischemia (Fig. 1). In accor- 
dance with our hypothesis relating available adenosine 
to systolic and diastolic functional recovery, ATP re- 
synthesizing capacity after an ischemic episode was de- 
pressed or abolished when adenosine deaminase was ad- 
ministered exogenously in cardioplegia. We speculate 
that the mechanism of adenosine deaminase’s action in 
this model is mediated through decreased availability of 
intracellular adenosine at reperfusion, thereby eliminat- 
ing or greatly altering the ability of the myocardium to 
resynthesize ATP. While intracellular adenosine is dif- 
ficult to demonstrate, myocardial levels of adenosine, as 
shown by HPLC from biopsies, were shown to correlate 
well with functional recovery. Accordingly, functional 
recovery was poor or nonexistent when adenosine re- 
serves were manipulated and depleted with adenosine 
deaminase. 
In previous studies, it was demonstrated that nucleo- 
tide levels decrease during ischemia [l-5]. Since ATP is 
essential for myocardial contraction and relaxation, any 
depletion of ATP, such as that seen during ischemia, 
may have a detrimental effect upon postischemic myo- 
cardial functional recovery. Reduction in myocardial 
ATP content has been correlated with the incomplete 
recovery of ventricular function observed following isch- 
emia [l]. 
Other investigations have demonstrated a favorable 
effect of ATP precursor enhancement on the recovery of 
ventricular function following ischemia [5, 61. In a 
previous study from this laboratory, for example [4], a 
beneficial effect of the exogenous adenosine on recovery 
of ventricular function was demonstrated in a isolated 
adult rabbit heart model. In that study, control hearts 
recovered 47 + 3% of their initial developed pressure 
following 2 hr of hypothermic (32’C) multidose cardio- 
plegic-induced ischemia and 45 min of reperfusion. 
Hearts receiving cardioplegia supplemented with 100, 
200, or 400 pM adenosine had significantly increased 
recovery of function (63 + 4%, 78 -+ 3%, and 70 + 4% of 
initial developed pressure, respectively). 
In a follow-up study [3] we determined if augmenta- 
tion of myocardial adenosine during global ischemia im- 
proves functional recovery by reducing depletion of ATP 
during ischemia or by enhancing repletion of ATP after 
reperfusion. Isolated adult rabbit hearts underwent 120 
min of mildly hypothermic ischemia (34°C). This study 
demonstrated that adenosine augmentation with exoge- 
nous adenosine or with 2-deoxycoformycin (a noncom- 
petitive inhibitor of adenosine deaminase) or the combi- 
nation of these agents significantly enhanced recovery 
of ventricular function following ischemia, as compared 
to standard cardioplegia-treated controls. Nucleotide 
levels in tissue biopsies were also measured by HPLC. 
During ischemia, adenosine levels were significantly ele- 
vated in the adenosine-augmented groups, but not in the 
control group. During ischemia, ATP decreased equally 
in all groups, indicating that augmenting myocardial 
adenosine had no effect on depletion of ATP during isch- 
emia. 
After reperfusion, ATP levels remained depressed in 
the control group, but increased in the adenosine-aug- 
mented groups above baseline values, suggesting that 
the improved functional recovery noted was due to accel- 
erated repletion and resynthesis of adenine nucleotide 
stores in the adenosine-augmented groups. 
Adenine nucleotides are resynthesized following isch- 
emia by two major pathways [7]. The first pathway is by 
de nouo synthesis of the nucleotide pool. However, this 
pathway is extremely slow and energy consuming [8]. 
The second or salvage pathway involves rephosphoryla- 
tion of adenosine to AMP by the enzyme adenosine ki- 
nase and subsequent regeneration of ATP. The salvage 
pathway is efficient and rapid, but it depends on the 
availability of intracellular adenosine as a precursor for 
ATP resynthesis. When there is depletion of intracellu- 
lar adenosine by degradation to inosine (catalyzed by 
adenosine deaminase) and washout of the nucleosides at 
reflow, then precursors are not available for the salvage 
pathway and resynthesis of ATP. We demonstrated in 
our previous study [3] that modification of adenosine 
deaminase activity can be an important determinant of 
intracellular nucleotide status and, potentially, recovery 
of postischemic function, because inhibition of adeno- 
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sine deaminase during ischemia with 2-deoxycoformy- represent an important potential strategy in cardiac sur- 
tin was beneficial in terms of functional recovery. gery. 
The uptake and salvage of adenosine and its break- 
down product inosine has been identified in isolated ma- 
ture cardiac myocytes [9] by measuring the distribution 
of radioactive precursor nucleotides incorporated into 
ATP, ADP, and AMP. When the maximum rates of the 
reactions in the nucleotide salvage pathway were calcu- 
lated, it was noted that myocytes have little capacity to 
salvage inosine. Additionally, inosine leaves the myo- 
cyte much faster than adenosine and by a passive mecha- 
nism. Adenosine is the favored substrate for the nucleo- 
tide salvage pathway, but the rate of adenosine salvage 
for intracellular adenosine is eight times the rate for ex- 
tracellular adenosine used as substrate for the salvage 
pathway. 
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